$1.25
1.57% today
Nasdaq, Apr 04, 09:43 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
about 7 hours ago
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
Neutral
GlobeNewsWire
3 days ago
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here.
Neutral
GlobeNewsWire
3 days ago
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of D...
Neutral
GlobeNewsWire
9 days ago
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS)
Neutral
GlobeNewsWire
16 days ago
Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) thus making IL-18 BPR more effective in vitro
Neutral
GlobeNewsWire
24 days ago
On-demand video webcast now available here
Neutral
GlobeNewsWire
about one month ago
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® )  provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Co...
Neutral
GlobeNewsWire
about one month ago
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today